{
    "organizations": [],
    "uuid": "a1c0e457085a3383d8e1a3143e397b230f172ffd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-abbvie-gets-positive-recommendatio/brief-abbvie-gets-positive-recommendation-from-pan-canadian-oncology-drug-review-for-venclexta-idUSFWN1QO0DR",
    "ord_in_thread": 0,
    "title": "BRIEF-AbbVie Gets Positive Recommendation From Pan-Canadian Oncology Drug Review For Venclexta",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - AbbVie Inc:\n* ABBVIE RECEIVES POSITIVE RECOMMENDATION FROM THE PAN-CANADIAN ONCOLOGY DRUG REVIEW FOR VENCLEXTA™ - AN ORAL THERAPY FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)\n* ABBVIE CANADA - PCODR CONDITIONALLY RECOMMENDS REIMBURSEMENT OF VENCLEXTA FOR CLL PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY & FAILED A BCRI​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-06T21:33:00.000+02:00",
    "crawled": "2018-03-07T19:34:10.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "receives",
        "positive",
        "recommendation",
        "oncology",
        "drug",
        "review",
        "oral",
        "therapy",
        "treatment",
        "patient",
        "chronic",
        "lymphocytic",
        "leukemia",
        "cll",
        "abbvie",
        "canada",
        "pcodr",
        "conditionally",
        "recommends",
        "reimbursement",
        "venclexta",
        "cll",
        "patient",
        "received",
        "least",
        "prior",
        "therapy",
        "failed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}